Showing 291-300 of 634 results for "".
Skin Cancer Prevention Through Photoprotection: What Your Patients Should Know
https://practicaldermatology.com/topics/skin-cancer-photoprotection/skin-cancer-prevention-through-photoprotection-what-your-patients-should-know/26540/Skin Cancer Prevention Through Photoprotection: What Your Patients Should KnowUV Risks, Cosentyx Update, ASDS Honorees
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-uv-risks-cosentyx-update-asds-honorees/18623/Teen indoor tanning may be linked with alcohol consumption in the past 30 days, marijuana use, and lifetime use of select illicit drugs, according to findings in JAMA Dermatology. L'Oréal unveiled My UV Patch this month at the Consumer Electronics Show. The stretchable skin sensor, to be introducedMonoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis Patients
https://practicaldermatology.com/topics/research-update/monoclonal-antibodies-restoring-healthy-skin-microbiome-atopic-dermatitis-patients/24566/Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis PatientsDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PAtopic Dermatitis Journal Club: AD Guidelines May Represent a ‘Paradigm Shift’ in Care
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/atopic-derm-journal-club-ad-guidelines-may-represent-a-paradigm-shift-in-care/24075/In the first video of this series, Derek Chu, MD and Peter Lio, MD talk about new atopic dermatitis (AD) guidelines from the American Academy of Allergy, Asthma and Immunology Joint Task Force. These guidelines potentially represent a reshaping of the approach to AD care and understanding, accordingASLMS New Beginnings Initiative
https://practicaldermatology.com/programs/practical-dermatology/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expandeThe Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availWhere is Dermatology Headed?
https://practicaldermatology.com/topics/psoriasis/where-is-dermatology-headed/18590/Neal Bhatia, MD and Joel Schlessinger, MD sit down as the medical editors of Practical Dermatology® to discuss the future of dermatology in this episode of Derm Insider. They talk about how an increased focus on research in the last few years is leading to new treatments and new understanding aboutThe Importance of Keeping Up with New Developments
https://practicaldermatology.com/conferences/maui-derm-2024/the-importance-of-keeping-up-with-new-developments/20257/Practical Dermatology® Chief Medical Editor Neal Bhatia, MD, chats with Resident Of Distinction Award-winner Dawn Queen, MD, at Maui Derm 2024, about the critical role of continuing to educate yourself as a practitioner, and the importance of keeping on top of new drugs and therapies in daily practiManaging Comorbidites of Psoriasis
https://practicaldermatology.com/topics/psoriasis/managing-comorbidites-of-psoriasis/18808/Ron Prussick, MD explains why it's important for dermatologists to discuss the risks of comorbidities such as cardiovascular events, fatty liver disease, depression, and more with patients with psoriasis. While it needs to be determined if the treatments used to treat the outside effects of psoriasi